DelveInsight's "VERZENIO Market Size, Forecast, and Market Insight Report" highlights the details around VERZENIO, which is a ...

DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the evolving Metabolic Dysfunction-Associated Steatohepatitis (MASH) market ...

The Government of Canada is committed to safeguarding the health and well-being of Canada's agricultural community while supporting the long-term sustainability and success of the sector. Today, ahead ...

Dr. Sarah M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

Eli Lilly and Company (NYSE:LLY) maintains a strong position with Verzenio in breast cancer, currently seeing about 15% of new patient starts going to their competitor in overlapping populations ...